[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370388-105":59,"doc-detail-370388-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","natural-bioactive-agents-testable-stem-cell-targeting-alternatives-for-therapy-resistant-breast-cancer","Natural Bioactive Agents - Testable Stem Cell-Targeting Alternatives for Therapy-Resistant Breast Cancer","","Long-term treatment options for conventional chemo-endocrine therapy and molecular-pathway-based targeted therapy are associated with acquired therapy resistance and the emergence of drug-resistant cancer-initiating stem cell populations, driving progression of metastatic breast cancer. Breast cancer subtypes defined by ER-α, PR, and/or HER-2 receptor expression respond differently to endocrine therapy or targeted regimens, while triple-negative breast cancer lacks receptor expression and relies on cytotoxic chemotherapy. Clinical limitations linked to modest responses motivate identifying stem cell targeting testable alternatives. The report surveys clinically relevant and drug-resistant cellular models and summarizes preclinical efficacy and mechanisms for natural phytochemicals and nutritional herbs as stem cell-targeting candidate bioactive agents.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/natural-bioactive-agents-testable-stem-cell-targeting-alternatives-for-therapy-resistant-breast-cancer/370388/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/natural-bioactive-agents-testable-stem-cell-targeting-alternatives-for-therapy-resistant-breast-cancer/370388.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does therapy resistance develop in breast cancer treatments?","Question",{"text":112,"@type":113},"Long-term conventional and targeted therapies can lead to acquired therapy resistance and the emergence of drug-resistant cancer-initiating stem cell populations that support metastatic progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do different breast cancer subtypes influence treatment choices?",{"text":117,"@type":113},"Treatment is guided by expression of ER-α, PR, and/or HER-2. Luminal A/B and HER-2-enriched subtypes respond to endocrine modulators or HER-2-targeted approaches, while triple-negative breast cancer lacks these receptors and relies on cytotoxic chemotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"What makes natural bioactive agents promising for therapy-resistant breast cancer?",{"text":121,"@type":113},"Naturally occurring dietary phytochemicals and nutritional herbs containing polyphenols, flavones, terpenes, saponins, lignans, and tannins show preclinical efficacy, lack systemic toxicity, and do not exhibit phenotypic drug resistance. They may provide testable stem cell-targeting alternatives.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370388,1791552126,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nNatural Bioactive Agents: Testable Stem Cell-Targeting Alternatives for Therapy-Resistant Breast Cancer  \nNitin T. Telang   \nAcademic Editor: Pyung-Hwan Kim  \nReceived: 20 January 2025  \nRevised: 17 February 2025  \nAccepted: 25 February 2025  \nPublished: 12 March 2025  \nCitation: Telang, N.T. Natural  \nBioactive Agents: Testable Stem Cell-Targeting Alternatives for Therapy-Resistant Breast Cancer. Int.  \nJ. Mol. Sci. 2025, 26, 2529 . [https://doi.org/](https://doi.org/)[ ](https://doi.org/)10.3390/ijms26062529  \nCopyright: © 2025 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \nCancer Prevention Research Program, Palindrome Liaisons Consultants, Montvale, NJ 07645-1559, USA; [ntelang3@gmail.com](ntelang3@gmail.com)  \nAbstract: Long-term treatment options for conventional chemo-endocrine therapy and molecular-pathway-based targeted therapy are associated with acquired therapy resistance and the emergence of drug-resistant cancer-initiating stem cell populations, leading to the progression of metastatic disease. These treatment options are based on the expression status of estrogen receptor-α (ER-α), progesterone receptor (PR) hormone receptors, and/or of human epidermal growth factor receptor-2 (HER-2) . The breast cancer subtypes Luminal A, Luminal B, and HER-2-enriched express hormone/growth factor receptors and exhibit a favorable response to hormone receptor modulators and growth factor receptor antagonists. The triple-negative breast cancer subtype lacks the expression of hormone/growth factor receptors and responds only to cytotoxic conventional chemotherapy. The clinical limitations, due to the modest therapeutic responses of chemo-resistant cancer-initiating stem cells, emphasize the need for the identification of stem cells targeting testable alternatives for therapy-resistant breast cancer. Developed drug-resistant stem cell models exhibit upregulated expression of select cellular biomarker tumor spheroid (TS) formations and cluster of differentiation44 (CD44), DNA-binding protein (NANOG), and octamer-binding protein-4 (OCT-4) molecular biomarkers that represent novel experimentally modifiable quantitative endpoints. Naturally occurring dietary phytochemicals and nutritional herbs containing polyphenols, flavones, terpenes, saponins, lignans, and tannins have documented human consumption, lack systemic toxicity, lack phenotypic drug resistance, and exhibit preclinical efficacy. Constituent bioactive agents may provide testable stem cell-targeting alternatives. The present report provides an overview of (i) clinically relevant cellular models and drugresistant cancer stem cell models for breast cancer subtypes,(ii) evidence for preclinical efficacy and mechanistic leads for natural phytochemicals and nutritional herbs, and (iii) the potential for the stem cell-targeting efficacy of natural bioactive agents as testable drug candidates for therapy-resistant breast cancer.  \nKeywords: cancer stem cells; drug resistance; natural products  \n1. Introduction  \nAdvanced-stage metastatic breast cancer represents a major cause of death in women. The American Cancer Society estimates 310,720 newly diagnosed breast cancer cases and 42,250 cancer-related deaths in women in 2025 [1] .  \nTreatment options for breast cancer are dictated by the expression status of hormone and growth factor receptors. The treatment of choice includes endocrine therapy for hormone receptors expressing the Luminal A subtype. This therapeutic option uses selective estrogen receptor modulators such as tamoxifen and raloxifen, selective estrogen receptor degraders such as flauvestrant, and aromatase inhibitors such as letrozole, exemestane, and  \nanastrozole. Human epidermal growth ","cbCaioPKYNkBmlrk","https://ap.wps.com/l/cbCaioPKYNkBmlrk","pdf",240786,11,"English","# Introduction\n## Breast cancer subtypes and receptor-driven treatment options\n## Therapy limitations and emergence of resistant cancer-initiating stem cells\n## Natural products as stem cell-targeting alternatives","[{\"question\":\"Why does therapy resistance develop in breast cancer treatments?\",\"answer\":\"Long-term conventional and targeted therapies can lead to acquired therapy resistance and the emergence of drug-resistant cancer-initiating stem cell populations that support metastatic progression.\"},{\"question\":\"How do different breast cancer subtypes influence treatment choices?\",\"answer\":\"Treatment is guided by expression of ER-α, PR, and/or HER-2. Luminal A/B and HER-2-enriched subtypes respond to endocrine modulators or HER-2-targeted approaches, while triple-negative breast cancer lacks these receptors and relies on cytotoxic chemotherapy.\"},{\"question\":\"What makes natural bioactive agents promising for therapy-resistant breast cancer?\",\"answer\":\"Naturally occurring dietary phytochemicals and nutritional herbs containing polyphenols, flavones, terpenes, saponins, lignans, and tannins show preclinical efficacy, lack systemic toxicity, and do not exhibit phenotypic drug resistance. They may provide testable stem cell-targeting alternatives.\"}]","Natural Bioactive Agents - Testable Stem Cell-Targeting Alternatives for Therapy-Resistant Breast Cancer | PDF",1790188273,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6fc4eae8735e333be3785d76888e1c78.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8ee5697e462f2e2645c2f99ebdc18d6.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0916715a105a2c90322895e91379f2fa.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e41f359e0e2a3de2ac21ac0e2ec4ccba.webp",980,1385]